Sponsor content
19 result(s) found, displaying 1 to 10
-
-
-
Cancellation by sponsorRequested by Beigene Aus Pty Ltd
-
-
Australian public assessment report (AusPar)Brukinsa (zanubritinib) was approved to treat adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients with deletion 17p and/or TP53 mutation.
-
Australian public assessment report (AusPar)Tevimbra (tislelizumab) has been approved for the treatment of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
Prescription medicine decision summaryTevimbra (tislelizumab) has been approved for the treatment of patients with various types of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
-
-